Neos Therapeutics Inc (NEOS) Sees Significant Increase in Short Interest

Neos Therapeutics Inc (NASDAQ:NEOS) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,582,254 shares, a growth of 7.5% from the March 15th total of 2,403,007 shares. Based on an average daily volume of 300,715 shares, the days-to-cover ratio is presently 8.6 days.

Several large investors have recently added to or reduced their stakes in NEOS. Vanguard Group Inc. raised its stake in Neos Therapeutics by 215.1% in the first quarter. Vanguard Group Inc. now owns 588,994 shares of the company’s stock valued at $4,241,000 after buying an additional 402,058 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Neos Therapeutics during the fourth quarter valued at approximately $545,000. Columbus Circle Investors raised its stake in Neos Therapeutics by 151.8% in the first quarter. Columbus Circle Investors now owns 106,520 shares of the company’s stock valued at $767,000 after buying an additional 64,216 shares during the last quarter. Hunter Associates Investment Management LLC acquired a new stake in Neos Therapeutics during the first quarter valued at approximately $360,000. Finally, State Street Corp raised its stake in Neos Therapeutics by 30.5% in the fourth quarter. State Street Corp now owns 154,361 shares of the company’s stock valued at $903,000 after buying an additional 36,058 shares during the last quarter. 34.32% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently commented on the stock. ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating and set a $8.75 price objective on the stock in a research note on Wednesday. Cowen and Company started coverage on shares of Neos Therapeutics in a research note on Wednesday, April 5th. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Neos Therapeutics in a research note on Saturday, March 11th.

Neos Therapeutics (NASDAQ:NEOS) opened at 8.30 on Friday. The company’s market capitalization is $187.25 million. Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $11.35. The firm has a 50-day moving average of $7.22 and a 200-day moving average of $6.67.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.87) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. Neos Therapeutics had a negative net margin of 1,013.17% and a negative return on equity of 144.74%. The firm had revenue of $5.63 million during the quarter. Equities analysts expect that Neos Therapeutics will post ($3.23) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://transcriptdaily.com/2017/05/20/short-interest-in-neos-therapeutics-inc-neos-rises-by-7-5-updated-updated-updated.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

12 Month Chart for NASDAQ:NEOS

Receive News & Ratings for Neos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply